Free Access
Med Sci (Paris)
Volume 32, Number 2, Février 2016
Page(s) 183 - 191
Section M/S Revues
Published online 02 March 2016
  1. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013 ; 72 : 1747–1755. [CrossRef] [PubMed] [Google Scholar]
  2. Elhai M, Meune C, Avouac J, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012 ; 51 : 1017–1026. [CrossRef] [PubMed] [Google Scholar]
  3. Elhai M, Avouac J, Walker UA, et al. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 2014 ; doi: 10.1136/annrheumdis-2014-206386. [Google Scholar]
  4. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013 ; 65 : 1953–1962. [CrossRef] [PubMed] [Google Scholar]
  5. Rabquer BJ, Hou Y, Del Galdo F, et al. The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1. Rheumatology (Oxford) 2009 ; 48 : 734–740. [CrossRef] [PubMed] [Google Scholar]
  6. Liu S, Parapuram SK, Leask A. Fibrosis caused by loss of PTEN expression in mouse fibroblasts is crucially dependent on CCN2. Arthritis Rheum 2013 ; 65 : 2940–2944. [CrossRef] [PubMed] [Google Scholar]
  7. Perros F, Humbert M, Cohen-Kaminsky S. Hypertension artérielle pulmonaire. Med Sci (Paris) 2013 ; 29 : 607–616. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  8. Ghatnekar A, Chrobak I, Reese C, et al. Endothelial GATA-6 deficiency promotes pulmonary arterial hypertension. Am J Pathol 2013 ; 182 : 2391–2406. [CrossRef] [PubMed] [Google Scholar]
  9. Derrett-Smith EC, Dooley A, Gilbane AJ, et al. Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension. Arthritis Rheum 2013 ; 65 : 2928–2939. [CrossRef] [PubMed] [Google Scholar]
  10. Maurer B, Distler A, Suliman YA, et al. Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Ann Rheum Dis 2014 ; 73 : 1880–1887. [CrossRef] [PubMed] [Google Scholar]
  11. Kuwana M, Okazaki Y. Brief report: impaired in vivo neovascularization capacity of endothelial progenitor cells in patients with systemic sclerosis. Arthritis Rheum 2014 ; 66 : 1300–1305. [CrossRef] [Google Scholar]
  12. Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheum 2014 ; 66 : 714–725. [CrossRef] [Google Scholar]
  13. Takahashi T, Asano Y, Ichimura Y, et al. Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis. Arthritis Rheum 2015 ; 67 : 254–265. [CrossRef] [Google Scholar]
  14. Fuschiotti P, Larregina AT, Ho J, et al. Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum 2013 ; 65 : 236–246. [CrossRef] [PubMed] [Google Scholar]
  15. Yoshizaki A, Yanaba K, Ogawa A, et al. Immunization with DNA topoisomerase I and Freund’s complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum 2011 ; 63 : 3575–3585. [CrossRef] [PubMed] [Google Scholar]
  16. Desallais L, Avouac J, Fréchet M, et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther 2014 ; 16 : R157. [CrossRef] [PubMed] [Google Scholar]
  17. Assassi S, Wu M, Tan FK, et al. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum 2013 ; 65 : 2917–2927. [CrossRef] [PubMed] [Google Scholar]
  18. Van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014 ; 370 : 433–443. [CrossRef] [PubMed] [Google Scholar]
  19. Arcand J, Robitaille G, Koenig M, et al. Heparin inhibits the interaction of DNA topoisomerase I/anti-topoisomerase I immune complexes with heparan sulfate on dermal fibroblasts. Arthritis Rheum 2012 ; 64 : 1632–1641. [CrossRef] [PubMed] [Google Scholar]
  20. Moroncini G, Grieco A, Nacci G, et al. Epitope specificity determines pathogenicity and detectability of anti-PDGFRα autoantibodies in systemic sclerosis. Arthritis Rheum 2015 ; 67 : 1891–1903. [CrossRef] [Google Scholar]
  21. Günther J, Kill A, Becker MO, et al. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther 2014 ; 16 : R65. [CrossRef] [PubMed] [Google Scholar]
  22. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014 ; 343 : 152–157. [CrossRef] [PubMed] [Google Scholar]
  23. Marangoni RG, Korman BD, Wei J, et al. Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. Arthritis Rheum 2015 ; 67 : 1062–1073. [CrossRef] [Google Scholar]
  24. Palumbo-Zerr K, Zerr P, Distler A, et al. Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis. Nat Med 2015 ; 21 : 150–158. [CrossRef] [PubMed] [Google Scholar]
  25. Wei J, Zhu H, Komura K, et al. A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses. Ann Rheum Dis 2014 ; 73 : 446–454. [CrossRef] [PubMed] [Google Scholar]
  26. Distler A, Ziemer C, Beyer C, et al. Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. Ann Rheum Dis 2014 ; 73 : 624–627. [CrossRef] [PubMed] [Google Scholar]
  27. Gerber EE, Gallo EM, Fontana SC, et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 2013 ; 503 : 126–130. [CrossRef] [PubMed] [Google Scholar]
  28. Dieudé P, Boileau C, Allanore Y. Immunogenetics of systemic sclerosis. Autoimmun Rev 2011 ; 10 : 282–290. [CrossRef] [PubMed] [Google Scholar]
  29. Radstake TR, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010 ; 42 : 426–429. [CrossRef] [PubMed] [Google Scholar]
  30. Allanore Y, Saad M, Dieudé P, et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 2011 ; 7 : e1002091. [CrossRef] [PubMed] [Google Scholar]
  31. Noda S, Asano Y, Nishimura S, et al. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun 2014 ; 5 : 5797. [CrossRef] [PubMed] [Google Scholar]
  32. Iwamoto N, Vettori S, Maurer B, et al. Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. Ann Rheum Dis 2016 ; 75 : 303–310. [CrossRef] [PubMed] [Google Scholar]
  33. Wipff J, Allanore Y, Boileau C. Interactions entre la fibrilline-1 et le TGF-β. Med Sci (Paris) 2009 ; 25 : 161–167. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.